Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320080 | 0.79 | RAB9A (0.48) | RAB9ANAMPTIDO1NPC1GAA | |
| SCHEMBL18418861 | 0.78 | NAMPT (0.40) | RAB9ANAMPTIDO1CYP17A1CA1 | |
| SCHEMBL14827198 | 0.74 | CNR2 (0.42) | RAB9ANPC1KMT2AMEN1BRD9 | |
| SCHEMBL23719141 | 0.74 | TSHR (0.53) | RAB9AIDO1NPC1KMT2ATP53 | |
| SCHEMBL18693864 | 0.72 | ALDH1A1 (0.56) | GAAHTTLMNA | |
| SCHEMBL6963518 | 0.71 | SCD (0.48) | NAMPTSCD | |
| SCHEMBL18925833 | 0.71 | ALDH1A1 (0.51) | GAAHTTLMNA | |
| SCHEMBL18694207 | 0.71 | MAPK13 (0.56) | GAASMN1; SMN2 | |
| SCHEMBL6970361 | 0.70 | RAB9A (0.50) | RAB9ANAMPTNPC1KMT2ABRD9 | |
| SCHEMBL18694788 | 0.70 | NTRK1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| CN-112823151-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3818044-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RAB9A 876/4885NAMPT 2899/4885IDO1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.